https://www.abc4.com/business/press-releases/cision/20250707LA24032/maplight-therapeutics-announces-initiation-of-phase-2-trial-of-its-novel-m1-m4-muscarinic-agonist-ml-007c-ma-for-the-treatment-of-schizophrenia/
About ML-007/PAC
ML-007C-MA, also referred to as ML-007C/PAC, is an oral, extended-release, fixed-dose combination of the investigational M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC). Potential differentiation for ML-007C-MA is driven by an optimized pharmacokinetic synchronization of its agonist and antagonist components in the periphery, without sacrificing strong activation of both M1 and M4 receptors in the central nervous system.
6 Likes
There will be a lot of antipsychotics that act on muscarinic receptors; they are the new trend.
1 Like
Yes, but when? Especily my part of the world (south eastern Europe).
3 Likes
That’s what makes me sad about the health system; it takes too long to process new medications to other continents.
1 Like